



São Paulo, May 05, 2026. RD Saúde (Raia Drogasil S.A. – B3: RADL3) announces its results for the 1<sup>st</sup> quarter of 2026 (1Q26). The Company's parent company and consolidated financial statements for the periods ended March 31, 2026 and 2025 have been prepared in accordance with the accounting practices adopted in Brazil, including the rules issued by the Brazilian Securities Commission (CVM), the Brazilian Accounting Standards – General Technical (NBC TG) and the pronouncements issued by the Brazilian Accounting Pronouncements Committee (CPC), and are in conformity with the International Financial Reporting Standards (IFRS) issued by the International Accounting Standards Board (IASB), and provide all the significant information related solely to the financial statements, which is consistent with the information used by management. The financial statements were prepared in Reais and all growth rates, unless otherwise stated, relate to the same period of the previous year.

**IFRS 16:** Our financial statements are prepared in accordance with IFRS 16. To better reflect the economic reality of the business, the figures presented in this report consider the pre-IFRS 16 standard with a reconciliation available in a dedicated section of this document.

**HIGHLIGHTS:**

- › **4BIO:** Closing on 05/04/26 for R\$ 792 MM + R\$ 67 MM in tax credits, **process effects disclosed as discontinued operations over Net Income** (detailed figures with and without 4Bio in a specific chapter);
- › **PHARMACIES:** **3.614 units in operation with 68 openings and 1 closure in the quarter;**
- › **GROSS REVENUE:** **R\$ 12.0 B, +20.4% growth and +12.8% MSSS in 4Q25, +9.7 pp greater than CMED;**
- › **MARKET SHARE:** **19.6% national share, a +1.5 pp increase with gains in every region;**
- › **DIGITAL:** **R\$ 3.6 B, an increase of 66.4% and retail penetration of 30.2% in the 1Q26;**
- › **ADJ. EBITDA:** **R\$ 821 MM, +31.7% growth & margin of 6.9% (+0.6 pp);**
- › **ADJ. NET INCOME (WITH 4BIO)\*:** **R\$ 300 MM, +69.2% growth & margin of 2.5% (+0.7 pp);**
- › **CASH FLOW:** **R\$ 285 MM positive free cash flow, R\$ 136 MM total cash generation.**

\* Includes the effects of taxation on investment subsidies, in accordance with the Law 14,789/2023.

**RADL3**  
**R\$ 21.50/share**  
Closing: May 04, 2026

**MARKET CAP**  
**R\$ 37,7 billion**

**NUMBER OF SHARES**  
**1,752,367,344**


**IR TEAM:**  
Flávio Correia  
André Stolfi  
Victor Torres  
Felipe Correa

**ir.rdsaude.com.br**  
**ri@rdsaude.com.br**

**New consolidated summary (ex-4Bio)**

In R\$ thousands	1Q25	2Q25	3Q25	4Q25	1Q26
<b># of pharmacies</b>	<b>3,301</b>	<b>3,371</b>	<b>3,453</b>	<b>3,547</b>	<b>3,614</b>
Organic openings	75	70	88	97	68
Closures	(4)	-	(6)	(3)	(1)
Headcount (EoP)	65,779	67,114	69,860	73,388	75,190
Pharmacist count (EoP)	13,462	13,734	13,981	14,377	14,965
# of tickets (thousands)	102,747	110,733	111,543	114,731	111,849
# of active customers (MM)	49.7	50.3	51.0	51.7	52.3
<b>Gross revenue</b>	<b>9,947,886</b>	<b>10,803,986</b>	<b>11,347,942</b>	<b>12,186,767</b>	<b>11,979,521</b>
Growth (YoY)	+10.7%	+13.1%	+15.5%	+22.3%	+20.4%
Gross profit	2,820,111	3,133,833	3,257,291	3,508,601	3,392,636
% of gross revenue	28.3%	29.0%	28.7%	28.8%	28.3%
<b>Adjusted EBITDA</b>	<b>623,161</b>	<b>862,980</b>	<b>892,592</b>	<b>924,318</b>	<b>820,786</b>
% of gross revenue	6.3%	8.0%	7.9%	7.6%	6.9%
<b>Adj. net income (w/ 4Bio)</b>	<b>177,107</b>	<b>402,744</b>	<b>401,986</b>	<b>361,654</b>	<b>299,752</b>
% of gross revenue	1.8%	3.7%	3.5%	3.0%	2.5%
<b>Free cash flow</b>	<b>(106,237)</b>	<b>(60,837)</b>	<b>615,609</b>	<b>(466,520)</b>	<b>284,869</b>


**STORE DEVELOPMENT**



We ended the 1Q26 with a total of 3,614 pharmacies in operation, opening 68 new units in 1Q26 and 323 LTM. We reiterate our guidance of 330-350 gross openings for 2026.

We closed 1 unit in 1Q26 totaling 10 in the LTM, with only 1 still in the maturation process. This equates to a low error ratio of 0.3% of the LTM openings, highlighting the precision of our expansion process. The remaining 9 closures were of mature units with an average of 15 years of operation, a result of the optimization of our portfolio, transferring revenues to our remaining nearby locations, releasing assets for efficient redeployment and eliminating fixed costs, thus increasing both the Company's EBITDA and ROIC.

At the end of 1Q26, a total of 25.2% of our pharmacies were still maturing and had not yet reached their full potential both in terms of revenue and profitability.




Our expansion continues to diversify our pharmacy network, both geographically and demographically. We have extended our presence to 674 cities in every state, +45 vs. 1Q25, a unique capillarity in Brazilian retail.


We maintained a consistent expansion pace in São Paulo, our largest market, sustaining 30% of last year's expansion plan. Even with our broad presence in the state, we continue to identify meaningful opportunities and see solid performance from newly opened stores, reinforcing the potential to grow profitably across the country.

Finally, the IRR of new stores has been increasing, reflecting greater accuracy in expansion decisions, supported by recent efficiency gains in operations, omnichannel, the growth of GLP-1 medicine, among other factors.

**Geographic presence**



**Retail Market Share**



Source: IQVIA. Southeast excludes SP.

Our more than 3.6 thousand pharmacies are present in every state in the country and supported by an integrated network of 15 distribution centers. This logistics grid allows us to serve more than 80% of our locations daily with lead times of up to 24 hours. As a result, we sustain high service levels, optimize working capital, and strengthen operational efficiency, establishing a significant competitive advantage.

Additionally, in the beginning of April, we initiated operations of our 16<sup>th</sup> DC. Located in the city of Itupeva/SP, this facility will strengthen our logistics network to sustain robust inventory management and the continued pharmacy network expansion.


Our national market share reached 19.6% in 1Q26, a robust gain of +1.5 pp vs. the prior year. In addition, we recorded relevant gains across all regions, demonstrating our competitive strength in diverse contexts and markets. Market shares reached 33.8% in São Paulo (+2.2 pp), 14.8% in the Southeast (+1.6 pp), 24.5% in the Midwest (+1.7 pp), 11.4% in the South (+0.4 pp), 14.6% in the Northeast (+1.3 pp), and 12.2% in the North (+1.3 pp).

We emphasize that we also recorded significant market share gains across all regions when excluding GLP-1 items and their substantial influence from our figures, which have benefited sales and share.

**DIGITAL, HEALTH AND CUSTOMER ENGAGEMENT**


**Digital sales and penetration**

R\$ millions, % of retail gross revenue




**Digital channel mix**

% of digital sales, 1Q26




**App NPS**




**Delivery mix**

% of digital sales, 1Q26



**Delivery NPS**

C&C, Delivered and CSCC



We continued to advance our digital strategy. In 1Q26, we recorded 267 million visits across our digital channels, an impactful audience that enhances our role in promoting health. In addition, digitalization increases spending per customer, with digitally engaged loyal customers spending 28% more than the average loyal customer.

As a result, our digital channels reached R\$ 3.6 billion in gross revenue in 1Q25, an absolute increase of R\$ 1.4 billion and growth of +66% compared to the 1Q25. The share of digital channels reached 30.2% of retail sales in 1Q25, an increase of +8.4 pp.


We highlight the growing use of our apps, ensuring that customers enjoy the best mobile experience specialized in omnichannel health and wellness journeys. Digital sales through this channel increased +77% vs. 1Q25, reaching an 83% share (+5 pp) of digital sales in the quarter.

This evolution in customer digitalization, leveraging our modern and proprietary channels, reflects the ongoing improvement of our mobile experience and a more complete, fully omnichannel health journey. It also capitalizes on the capillarity of our store network, which has 95% of the A-Class population within a 1.5 km radius. This growing proximity, strengthened by our profitable organic expansion, constitutes another important competitive advantage by enabling 97% of digital orders to be delivered or picked up in less than 60 minutes with high economic efficiency.


Finally, we continued to strengthen the role of our pharmacies in customers' integral health journey, positioning them as health hubs within the communities we serve and expanding engagement through pharmaceutical services. We now have 3.0 thousand units with *Mais Saúde* hubs and their expanded services portfolio, in addition to 430 units enabled for vaccination. In 1Q26, more than 1.4 million pharmaceutical services were performed, including CATs (clinical analysis tests), vaccinations, and other services, recording an NPS superior to the pharmacy average.

**↔ GROSS REVENUES**

**Consolidated gross revenues**




**Retail sales mix**




In a quarter without calendar effects, we ended 1Q26 with R\$ 11,980 million in gross revenue, a growth of 20.4% vs. 1Q25. The slight deceleration vs. 4Q25 was due to the peak of sales recorded on Black Friday in that quarter.

Across categories, Branded Rx was the highlight, growing +29.3% for the quarter and mainly driven by GLP-1 medication, sustaining a similar penetration as in 4Q25. Generics grew +17.7% due to the recent expiration of several patents and OTC advanced +14.4%, in line with expectations. Lastly, HPC recorded a healthy growth of +11.7%, despite seasonal items facing an atypically cool and rainy summer in the Southeast.


**Consolidated revenue growth**



**Same-Store sales growth – Retail**




**Mature-Store sales growth – Retail**



■ CMED price adjustment    ■ Real growth


Finally, we recorded average same-store sales growth of +14.3% in 1Q26. Among mature stores, which completed the full 3-year ramp-up, we posted average growth of +12.8% in the 1Q26, a pace 9.7 pp above the 3.1% CMED price adjustment authorized in 2025 and 8.7 pp above the LTM CPI.

↔ **GROSS PROFIT**



Gross profit totaled R\$ 3,392.6 million in the quarter, equivalent to a gross margin of 28.3%. We recorded a 0.4 pp pressure vs. 1Q25 due to higher share of GLP-1 in the sales mix and 0.1 pp from the non-cash Net Present Value (NPV) adjustment, offset by 0.4 pp in commercial gains a 0.1 pp improvement in inventory losses.


↔ **SELLING EXPENSES**



Selling expenses totaled R\$ 2,275.2 million in 1Q26, equivalent to 19.0% of gross revenue, a dilution of 0.1 pp vs. the prior year.


In the 4Q25, we performed a 0.5 pp investment into our employee value proposition (EVP) in order to strengthen team engagement and customer NPS. This structural investment was partially offset by strong mature-store growth above inflation and additional dilutions in expenses with rentals and payment methods.

↔ **GENERAL & ADMINISTRATIVE EXPENSES**




General and administrative expenses totaled R\$ 296.6 million in the quarter, nominally neutral in comparison to 1Q25 and corresponding to 2.5% of gross revenue, a dilution of 0.5 pp. This dilution reflects a 0.2 pp gain in personnel expenses, primarily due to the corporate restructuring carried out in the 2Q25 aimed at greater efficiency and agility in management, in addition to 0.3 pp in other expenses.

↔ **EBITDA**



We recorded an adjusted EBITDA of R\$ 820.8 million in 1Q26, an increase of 31.7% compared to 1Q25. EBITDA margin reached 6.9%, an increase of 0.6 pp.

**DEPRECIATION, NET FINANCIAL EXPENSES AND EBT**




\* Includes the effects of taxation on investment subsidies, in accordance with the Law 14,789/2023.

Adjusted depreciation expenses totaled R\$ 272.5 million in 1Q26, equivalent to 2.3% of gross revenue for the year, a dilution of 0.2 pp vs. 1Q25.

Adjusted net financial expenses totaled R\$ 215.3 million, representing 1.8% of gross revenue, stable vs. 1Q25. Of the total amount, R\$ 171.1 million refers to the actual financial interest accrued on financial liabilities, equivalent to 1.4% of gross revenue with a 0.3 pp increase, driven by a higher SELIC rate and a larger financial liability balance. Additionally, R\$ 44.2 million refers to the non-cash NPV adjustment, equivalent to 0.4% of gross revenue with a 0.3 pp decrease vs. 1Q25.

Lastly, we recorded an adjusted EBT of R\$ 332.9 million, a 70.2% increase. This was equivalent to a margin of 2.8% of gross revenue with a 0.8 pp increase vs. the same period of the previous year.

**INCOME TAXES AND NET INCOME**



\* Includes the effects of taxation on investment subsidies, in accordance with the Law 14,789/2023.

\*\* Effective tax rate.

We provisioned a total of R\$ 49.6 million in adjusted income tax in 1Q26, equivalent to 0.4% of gross revenue, an increase of 0.1 pp vs. 1Q25. The effective tax rate for 1Q26 was 14.9% of EBT, a reduction of 2.2 pp compared to 1Q25.

On May 04<sup>th</sup> 2026 we concluded the sale of 4Bio, with its effects classified as discontinued operations. The consolidated adjusted net income for the period totaled R\$ 299.8 million (+69.2% vs. 1Q25) with a margin of 2.5% of gross revenue (+0.7 pp). Excluding the discontinued operations of 4Bio, we recorded an adjusted net income of R\$ 283.3 million, a 74.7% increase vs. 1Q25.


We highlight that the payment for the 4Bio's transaction will occur in 6 yearly installments or R\$ 100.0 MM each, adjusted by the DI rate and with the first payment in 2Q26, in addition to estimated payments of R\$ 65.1 MM in working capital adjustments, R\$ 127.3 MM in superveniences related to DIFAL judicial recoveries and R\$ 66.7 MM in income tax credits. These resources will be part of our recurrent results for the next years and will strengthen our capital structure, reduce our financial leverage and increase our profitability.

**EBITDA & NET INCOME RECONCILIATION AND NON-RECURRING RESULTS**

<b>Adjusted EBITDA &amp; Net Income Reconciliation (R\$ millions)</b>	<b>1Q26</b>	<b>1Q25</b>
<b>Net income</b>	<b>173.2</b>	<b>181.1</b>
Results of discontinued operations (4Bio)	(11.7)	(22.8)
Income tax	(13.1)	31.5
Equity equivalence	0.2	1.4
Financial result	203.2	178.8
<b>EBIT (ex-4Bio)</b>	<b>351.8</b>	<b>370.1</b>
Depreciation and amortization	272.5	247.3
<b>EBITDA (ex-4Bio)</b>	<b>624.2</b>	<b>617.4</b>
Asset write-offs, including 4Bio	196.8	2.0
Social investments and donations	4.1	3.6
Tax effects from previous years	(5.0)	(63.2)
Other non-recurring/non-operating effects	0.6	63.4
<b>Adjusted EBITDA (ex-4Bio)</b>	<b>820.8</b>	<b>623.2</b>
<b>Net income</b>	<b>173.2</b>	<b>181.1</b>
Net non-rec. effects of discount. operations (4Bio)	4.8	(7.8)
Non-recurring EBITDA effects	196.5	5.8
Non-recurring financial revenues	(12.0)	-
Non-rec. effects of cont. op. on income taxes (34%)	(62.7)	(2.0)
<b>Adjusted net income</b>	<b>299.8</b>	<b>177.1</b>

Within our EBITDA, we recorded R\$ 196.5 million in net non-recurring expenses in the 1Q26. This includes R\$ 196.8 million in asset write-offs, with R\$ 196.0 million stemming from the sale of 4Bio, R\$ 4.1 million in social investments & donations and R\$ 5.0 million in gains related to tax effects of previous years, as well as R\$ 0.6 million in other non-recurring effects. In net income, we recorded net non-recurring effects of R\$ 4.8 million in 4Bio, non-recurring gains of R\$ 12.0 million in financial revenues stemming from the monetary correction of tax credits from previous years, and a R\$ 62.7 million reduction in income taxes, of which R\$ 66.7 million are credits resulting from the sale of 4Bio.

**CASH CYCLE**



\* Adjusted for discounted receivables & advanced payments to suppliers.

We recorded a cash cycle of 53.8 days in 1Q26, a reduction of 9.8 days compared to the same period of last year, adjusted for discounted receivables and advanced payments to suppliers. This improvement was driven primarily by a reduction of 8.8 days in inventories and an increase of 3.3 days in suppliers, more than offsetting an increase of 2.3 days in receivables.

We highlight that we had the end of the ICMS-ST tax regime in the state of SP, with the charges now being upon gross revenue and removing its effects from COGS and from inventories within the state. The new tax regime resulted in a cash cycle reduction of approximately 3.0 days and in tax credits that are expected to be recovered over the next 12 months.

## ↔ CASH FLOW

Cash flow (R\$ millions)	1Q25 Ex-4Bio	1Q26
<b>Adjusted EBIT</b>	<b>375.9</b>	<b>548.3</b>
NPV adjustment	(64.8)	(63.3)
Non-recurring effects	(5.8)	(184.5)
Income tax (34%)	(103.8)	(102.2)
Depreciation	246.7	272.3
Impairment provision (4Bio)	-	196.1
Others	(8.4)	29.0
<b>Resources from operations</b>	<b>439.8</b>	<b>695.8</b>
Cash cycle*	(238.5)	800.8
Other assets (liabilities)**	(40.7)	(963.6)
<b>Operating cash flow</b>	<b>160.6</b>	<b>533.0</b>
Investments	(266.9)	(248.2)
<b>Free cash flow</b>	<b>(106.2)</b>	<b>284.9</b>
M&A and other investments	(53.3)	(86.9)
Interest on equity and dividends	(0.1)	(0.5)
Net financial expenses***	(113.3)	(171.1)
Tax benefit (fin. exp., loE, dividends)	78.7	109.3
<b>Total cash flow (ex-4Bio)</b>	<b>(194.3)</b>	<b>135.7</b>
Effects from discontinued operations (4Bio)	(31.6)	23.6
<b>Total cash flow (with 4Bio)</b>	<b>(162.6)</b>	<b>112.0</b>

\*Includes adjustments to discounted receivables.

\*\*Includes NPV adjustments.

\*\*\*Excludes NPV adjustments.

We generated R\$ 695.8 million in resources from operations in 1Q26 (equivalent to 5.8% of gross revenue), operating cash flow totaled R\$ 533,0 million. During the period, CAPEX amounted to R\$ 248.2 million, of which R\$ 117.6 million were used for the opening of new pharmacies, R\$ 54.2 million to maintenance and renovation of existing units, R\$ 50.3 million for IT, R\$ 15.1 million in logistics, and R\$ 10.9 million in other projects.

Net financial expenses resulted in a cash outflow of R\$ 171.1 million in 1Q26. These expenses were partially offset by a tax deduction of R\$ 109.3 million related to financial expenses and interest on equity (loE). Finally, we announced R\$150.4 million in interest on equity (loE) in 1Q26, compared with R\$ 118.1 million in 1Q25.

## ↔ INDEBTEDNESS

Net Debt (R\$ millions)	1Q25	2Q25	3Q25	4Q25	1Q26
Short-term Debt	672.2	849.7	522.5	508.1	425.5
Long-term Debt	2,408.5	2,758.6	2,760.1	3,359.6	3,236.1
<b>Total Gross Debt</b>	<b>3,080.7</b>	<b>3,608.3</b>	<b>3,282.6</b>	<b>3,867.8</b>	<b>3,661.5</b>
(-) Cash and Equivalents	352.3	376.3	339.6	358.6	441.8
<b>Net Debt</b>	<b>2,728.4</b>	<b>3,232.0</b>	<b>2,943.0</b>	<b>3,509.1</b>	<b>3,219.7</b>
Discounted Receivables	803.2	761.2	514.7	800.3	953.6
Advances to suppliers	(3.7)	(13.2)	(3.7)	-	-
Investment Put/Call options (estimated)	14.0	14.4	22.8	15.5	15.9
<b>Adjusted Net Debt</b>	<b>3,541.8</b>	<b>3,994.4</b>	<b>3,476.7</b>	<b>4,324.9</b>	<b>4,189.2</b>
LTM Adjusted EBITDA	2,935.8	2,974.4	3,056.3	3,303.1	3,500.7
<b>Adjusted Net Debt / EBITDA</b>	<b>1.2x</b>	<b>1.3x</b>	<b>1.1x</b>	<b>1.3x</b>	<b>1.2x</b>


We ended the 1Q26 with adjusted net debt of R\$ 4,189.2 million, corresponding to a financial leverage ratio of 1.2x adjusted EBITDA for the last 12 months, stable vs. 4Q24. Our adjusted net debt considers a balance of R\$ 953.6 million in discounted receivables and R\$ 15.9 million in obligations related to put/call options for remaining equity interests in investee companies.

Gross debt totaled R\$ 3,661.5 million, fully comprised by the issuance of Debentures and Real Estate Receivables Certificates (CRIs), all with a reaffirmed AAA.br rating from Moody's. Of total indebtedness, 88% is long-term and 12% is short-term. We ended the quarter with a total cash and equivalents position of R\$ 441.8 million.

It is important to mention that the sales growth above 20% over the past two quarters demanded a relevant investment in working capital temporarily limiting the reduction of our financial leverage, despite being partly offset by the significant reduction in our cash cycle. However, we expect a reduction in financial leverage over the course of the year due to the proceeds from the sale of 4Bio, the recovery of ICMS on inventories in São Paulo and the cash generation from operations.

◆ **TOTAL SHAREHOLDER RETURNS**

**Stock price appreciation**



Our share price decreased 0.7% in 1Q26, while the IBOVESPA increased by 16.8%. During the period, the average daily trading volume (ADTV) was R\$ 243 million. Since the IPO of Drogasil in June 2007, we achieved a cumulative share appreciation of 2,872%, compared to only 245% for the IBOVESPA.

Including the payment of interest on equity and dividends, we generated an average annual total return to shareholders of 20.5%. Considering the IPO of Raia in December 2010, the cumulative return amounted to 757%, compared to 176% for the IBOVESPA. Including shareholder distributions, this equates to an average annual return of 15.8%.

◆ **4BIO SALE DEVELOPMENTS**

We concluded on May 04<sup>th</sup> 2026 the sale of 4Bio. Starting in 1Q26, we will report resubmitted 2025 results treating 4Bio effects as Discontinued Operations. To allow for a transparent analysis, we present below the previous 2025 consolidated results (including 4Bio) and the new consolidated /continued operations results (ex-4Bio):

Consolidated adjusted income statement (R\$ thousands)	Previous consolidated					New consolidated / Continued Operations				
	1Q25	2Q25	3Q25	4Q25	2025	1Q25	2Q25	3Q25	4Q25	2025
						Resubmitted	Resubmitted	Resubmitted	Resubmitted	Resubmitted
<b>Gross revenue</b>	<b>10,820,630</b>	<b>11,656,073</b>	<b>12,117,999</b>	<b>13,014,924</b>	<b>47,609,626</b>	<b>9,947,886</b>	<b>10,803,986</b>	<b>11,347,942</b>	<b>12,186,767</b>	<b>44,286,581</b>
Taxes, deductions and returns	(769,620)	(825,030)	(853,084)	(911,443)	(3,359,177)	(674,904)	(729,303)	(767,440)	(817,575)	(2,989,221)
<b>Net revenue</b>	<b>10,051,010</b>	<b>10,831,043</b>	<b>11,264,915</b>	<b>12,103,481</b>	<b>44,250,449</b>	<b>9,272,982</b>	<b>10,074,683</b>	<b>10,580,502</b>	<b>11,369,193</b>	<b>41,297,360</b>
Cost of goods sold	(7,169,700)	(7,632,427)	(7,950,560)	(8,540,193)	(31,292,878)	(6,452,872)	(6,940,850)	(7,323,211)	(7,860,591)	(28,577,524)
<b>Gross profit</b>	<b>2,881,310</b>	<b>3,198,617</b>	<b>3,314,356</b>	<b>3,563,288</b>	<b>12,957,571</b>	<b>2,820,111</b>	<b>3,133,833</b>	<b>3,257,291</b>	<b>3,508,601</b>	<b>12,719,836</b>
Selling expenses	(1,933,963)	(2,015,209)	(2,094,934)	(2,290,200)	(8,334,306)	(1,902,460)	(1,982,851)	(2,064,781)	(2,258,851)	(8,208,943)
General and administrative expenses	(303,255)	(298,397)	(310,170)	(336,674)	(1,248,495)	(294,489)	(288,002)	(299,919)	(325,432)	(1,207,842)
<b>Operational expenses</b>	<b>(2,237,218)</b>	<b>(2,313,605)</b>	<b>(2,405,104)</b>	<b>(2,626,874)</b>	<b>(9,582,801)</b>	<b>(2,196,949)</b>	<b>(2,270,853)</b>	<b>(2,364,700)</b>	<b>(2,584,283)</b>	<b>(9,416,785)</b>
<b>Adjusted EBITDA</b>	<b>644,092</b>	<b>885,011</b>	<b>909,252</b>	<b>936,414</b>	<b>3,374,770</b>	<b>623,161</b>	<b>862,980</b>	<b>892,592</b>	<b>924,318</b>	<b>3,303,051</b>
Depreciation and amortization	(248,356)	(252,651)	(265,977)	(275,856)	(1,042,839)	(247,287)	(251,535)	(264,817)	(274,659)	(1,038,298)
<b>Operational earnings before financial results</b>	<b>395,736</b>	<b>632,361</b>	<b>643,275</b>	<b>660,559</b>	<b>2,331,930</b>	<b>375,874</b>	<b>611,445</b>	<b>627,775</b>	<b>649,660</b>	<b>2,264,753</b>
Financial expenses	(280,045)	(336,271)	(346,255)	(393,738)	(1,356,309)	(265,006)	(310,428)	(340,850)	(369,879)	(1,286,162)
Financial revenue	104,456	134,410	155,948	141,351	536,165	86,174	106,401	129,924	116,093	438,592
<b>Financial results</b>	<b>(175,589)</b>	<b>(201,861)</b>	<b>(190,307)</b>	<b>(252,387)</b>	<b>(820,144)</b>	<b>(178,831)</b>	<b>(204,027)</b>	<b>(210,926)</b>	<b>(253,786)</b>	<b>(847,570)</b>
Equity equivalence	(1,429)	(467)	1,034	2,701	1,839	(1,429)	(467)	1,034	2,701	1,839
<b>Earnings before income tax and social charges</b>	<b>218,718</b>	<b>430,033</b>	<b>454,002</b>	<b>410,872</b>	<b>1,513,625</b>	<b>195,614</b>	<b>406,951</b>	<b>417,883</b>	<b>398,574</b>	<b>1,419,022</b>
Income tax and social charges	(41,611)	(27,289)	(52,016)	(49,218)	(170,134)	(33,469)	(62,941)	(71,071)	(48,402)	(215,881)
<b>Adjusted net income ex-4Bio</b>	<b>177,107</b>	<b>402,744</b>	<b>401,986</b>	<b>361,654</b>	<b>1,343,491</b>	<b>162,145</b>	<b>344,011</b>	<b>346,812</b>	<b>350,172</b>	<b>1,203,140</b>
Results of discontinued operations						14,962	58,734	55,174	11,481	140,351
<b>Adjusted net income</b>	<b>177,107</b>	<b>402,744</b>	<b>401,986</b>	<b>361,654</b>	<b>1,343,491</b>	<b>177,107</b>	<b>402,744</b>	<b>401,986</b>	<b>361,654</b>	<b>1,343,491</b>

Assets (R\$ thousands)	Previous consolidated				New consolidated / Continued Operations			
	1Q25	2Q25	3Q25	4Q25	1Q25	2Q25	3Q25	4Q25
Cash and cash equivalents	404,382	527,020	436,340	509,619	352,269	376,334	339,615	358,636
Financial investments	65,795	78,278	102,050	19,120	65,795	78,278	102,050	19,120
Accounts receivable	2,826,909	3,026,697	3,408,229	3,400,587	2,090,777	2,373,076	2,848,274	2,833,401
Inventories	8,600,742	8,322,965	8,497,508	9,576,342	8,213,536	7,948,264	8,125,437	9,132,736
Taxes receivable	475,578	478,634	510,126	541,293	433,918	436,987	466,246	519,282
Anticipated expenses	145,736	154,378	117,793	116,027	145,122	151,808	115,993	115,064
Judicial deposits	3,017	4,060	6,825	4,970	3,017	4,060	6,825	4,970
Assets of investment for sale (4Bio)	-	-	-	-	1,641,850	1,658,025	1,504,998	1,626,652
Other accounts receivable	585,521	685,517	674,372	736,416	522,843	609,794	608,926	679,778
<b>Current assets</b>	<b>13,107,679</b>	<b>13,277,550</b>	<b>13,753,242</b>	<b>14,904,373</b>	<b>13,469,126</b>	<b>13,636,626</b>	<b>14,118,364</b>	<b>15,289,638</b>
Deposit in court	255,852	266,589	295,666	296,349	27,578	32,718	58,853	61,239
Taxes receivable	231,961	229,824	239,307	255,077	215,553	225,666	233,345	227,331
Income tax and social charges deferred	153,299	156,513	154,495	153,345	48,181	48,182	46,164	45,014
Other credits	19,864	14,928	9,951	7,589	19,864	14,928	9,951	7,589
Investments	13,663	13,447	16,660	19,603	13,663	13,447	16,660	19,603
Property, plant and equipment	2,698,393	2,744,191	2,830,643	2,942,880	2,693,141	2,737,578	2,822,576	2,934,657
Intangible	2,018,105	2,043,075	2,070,676	2,051,563	2,011,710	2,036,972	2,064,727	2,045,709
<b>Non-current assets</b>	<b>5,391,137</b>	<b>5,468,568</b>	<b>5,617,397</b>	<b>5,726,407</b>	<b>5,029,690</b>	<b>5,109,491</b>	<b>5,252,276</b>	<b>5,341,142</b>
<b>TOTAL ASSETS</b>	<b>18,498,816</b>	<b>18,746,118</b>	<b>19,370,640</b>	<b>20,630,780</b>	<b>18,498,816</b>	<b>18,746,118</b>	<b>19,370,640</b>	<b>20,630,780</b>

Liabilities and shareholder equity (R\$ thousands)	Previous consolidated				New consolidated / Continued Operations			
	1Q25	2Q25	3Q25	4Q25	1Q25	2Q25	3Q25	4Q25
Suppliers	6,061,553	5,657,667	6,122,839	6,922,978	5,577,390	5,192,141	5,739,195	6,429,186
Loans and financing	763,466	944,229	522,497	508,137	672,158	849,691	522,497	508,137
Salaries and social charges payable	659,892	793,421	911,664	772,590	646,954	777,866	895,260	757,550
Taxes payable	400,324	403,675	472,453	417,176	377,395	384,088	453,140	397,995
Dividends and interest on equity	343,003	217,181	338,196	2,566	343,003	217,181	338,196	2,566
Provision for lawsuits	86,280	77,279	48,336	58,221	86,280	77,279	48,336	58,221
Liabilities of investment for sale (4Bio)	-	-	-	-	839,141	796,567	551,325	662,887
Other accounts payable	475,445	433,872	459,044	495,507	457,459	415,224	442,815	478,667
<b>Current liabilities</b>	<b>8,789,963</b>	<b>8,527,324</b>	<b>8,875,030</b>	<b>9,177,174</b>	<b>8,999,781</b>	<b>8,710,038</b>	<b>8,990,764</b>	<b>9,295,209</b>
Loans and financing	2,408,492	2,758,638	2,760,116	3,359,618	2,408,492	2,758,638	2,760,116	3,359,618
Provision for lawsuits	293,523	284,626	255,049	248,853	84,145	102,133	143,283	135,298
Income tax and social charges deferred	38,276	25,503	2,356	8,609	38,276	25,503	2,356	8,609
Other accounts payable	101,215	77,846	68,917	86,971	100,774	77,625	64,948	82,491
<b>Non-current liabilities</b>	<b>2,841,506</b>	<b>3,146,613</b>	<b>3,086,437</b>	<b>3,704,050</b>	<b>2,631,687</b>	<b>2,963,899</b>	<b>2,970,703</b>	<b>3,586,016</b>
Common stock	4,000,000	4,000,000	4,000,000	4,750,000	4,000,000	4,000,000	4,000,000	4,750,000
Capital reserves	117,894	131,107	125,346	139,291	117,894	131,107	125,346	139,291
Revaluation reserve	11,054	11,022	10,991	10,960	11,054	11,022	10,991	10,960
Income reserves	2,529,320	2,529,320	2,529,320	2,489,084	2,529,320	2,529,320	2,529,320	2,489,084
Accrued income	62,099	322,824	666,109	-	62,099	322,824	666,109	-
Equity adjustments	62,969	62,969	62,969	62,969	62,969	62,969	62,969	62,969
Non controller interest	14,117	14,939	14,437	14,069	14,117	14,939	14,437	14,069
Additional dividend proposed	69,895	-	-	283,184	69,895	-	-	283,184
<b>Shareholder equity</b>	<b>6,867,348</b>	<b>7,072,180</b>	<b>7,409,172</b>	<b>7,749,555</b>	<b>6,867,348</b>	<b>7,072,180</b>	<b>7,409,172</b>	<b>7,749,555</b>
<b>TOTAL LIABILITIES &amp; SHAREHOLDER EQUITY</b>	<b>18,498,816</b>	<b>18,746,118</b>	<b>19,370,640</b>	<b>20,630,780</b>	<b>18,498,816</b>	<b>18,746,118</b>	<b>19,370,640</b>	<b>20,630,780</b>

Cash flow (R\$ millions)	Previous consolidated				New consolidated / Continued Operations			
	1Q25	2Q25	3Q25	4Q25	1Q25 Ex-4Bio	2Q25 Ex-4Bio	3Q25 Ex-4Bio	4Q25 Ex-4Bio
<b>Adjusted EBIT</b>	<b>395.7</b>	<b>632.4</b>	<b>643.3</b>	<b>660.6</b>	<b>375.9</b>	<b>611.4</b>	<b>627.8</b>	<b>649.7</b>
NPV adjustment	(64.3)	(63.2)	(69.8)	(78.8)	(64.8)	(65.5)	(71.1)	(78.2)
Non-recurring effects	6.1	(2.9)	112.3	(81.3)	(5.8)	(2.8)	56.2	(79.0)
Income tax (34%)	(114.8)	(192.6)	(233.1)	(170.1)	(103.8)	(184.7)	(208.4)	(167.4)
Depreciation	247.8	252.4	256.4	287.0	246.7	251.3	255.2	285.8
Others	41.4	(6.5)	60.8	24.2	(8.4)	(14.6)	125.2	18.0
<b>Resources from operations</b>	<b>512.0</b>	<b>619.7</b>	<b>769.7</b>	<b>641.4</b>	<b>439.8</b>	<b>595.2</b>	<b>784.9</b>	<b>628.8</b>
Cash cycle*	(276.6)	(264.1)	131.9	(563.6)	(238.5)	(333.5)	123.5	(588.8)
Other assets (liabilities)**	(42.3)	(3.0)	113.3	(81.3)	(40.7)	(6.9)	74.4	(96.8)
<b>Operating cash flow</b>	<b>193.1</b>	<b>352.5</b>	<b>1,014.9</b>	<b>(3.5)</b>	<b>160.6</b>	<b>254.8</b>	<b>982.7</b>	<b>(56.8)</b>
Investments	(266.9)	(315.6)	(367.1)	(409.8)	(266.9)	(315.6)	(367.1)	(409.8)
<b>Free cash flow</b>	<b>(73.8)</b>	<b>36.9</b>	<b>647.8</b>	<b>(413.2)</b>	<b>(106.2)</b>	<b>(60.8)</b>	<b>615.6</b>	<b>(466.5)</b>
M&A and other investments	(53.7)	(20.3)	(34.2)	61.8	(53.3)	(17.9)	(31.5)	63.1
Interest on equity and dividends	(0.1)	(308.3)	(0.1)	(344.3)	(0.1)	(308.3)	(0.1)	(344.3)
Income tax paid over interest on equity	-	(15.4)	(18.4)	(39.9)	-	(15.4)	(18.4)	(39.9)
Net financial expenses***	(113.9)	(143.9)	(128.4)	(163.2)	(113.3)	(143.8)	(145.1)	(166.5)
Tax benefit (fin. exp., IoE, dividends)	78.9	93.8	91.5	104.9	78.7	93.7	97.2	106.1
<b>Total Cash Flow (ex-4Bio)</b>					<b>(194.3)</b>	<b>(452.6)</b>	<b>517.7</b>	<b>(848.2)</b>
Effects from discontinued operations (4Bio)					(31.6)	(95.3)	(40.6)	(54.3)
<b>Total Cash Flow (with 4Bio)</b>	<b>(162.6)</b>	<b>(357.2)</b>	<b>558.3</b>	<b>(793.9)</b>	<b>(162.6)</b>	<b>(357.2)</b>	<b>558.3</b>	<b>(793.9)</b>

\*Includes adjustments to discounted receivables.

\*\*Includes NPV adjustments.

\*\*\*Excludes NPV adjustments.

## IFRS-16

Since 2019, the financial statements have been prepared in accordance with IFRS 16. However, for historical comparability purposes, the figures presented in this report exclude the effects of this standard, as we believe the previous accounting approach better reflects the economic reality of our business. On RD Saúde's Investor Relations website ([ir.rdsaude.com.br](http://ir.rdsaude.com.br)), the financial statements can be found in the 'Results Spreadsheets' section.

Income Statement (R\$ millions)	1Q26		Change Δ 1Q26
	Pre IFRS 16	IFRS 16	
<b>Gross Revenue</b>	<b>11,979.5</b>	<b>11,979.5</b>	<b>(0.0)</b>
<b>Gross Profit</b>	<b>3,392.6</b>	<b>3,394.3</b>	<b>1.7</b>
Gross Margin	28.3%	28.3%	0.0 pp
Selling Expenses	(2,275.2)	(1,924.6)	350.6
G&A	(296.6)	(295.8)	0.8
<b>Total Expenses</b>	<b>(2,571.8)</b>	<b>(2,220.4)</b>	<b>351.4</b>
as % of Gross Revenue	21.5%	18.5%	(3.0 pp)
<b>Adjusted EBITDA</b>	<b>820.8</b>	<b>1,173.9</b>	<b>353.1</b>
as % of Gross Revenue	6.9%	9.8%	2.9 pp
Non-Recurring Expenses / Revenues	(196.5)	(195.4)	1.1
Depreciation and Amortization	(272.5)	(524.8)	(252.3)
Financial Results	(203.2)	(326.7)	(123.4)
Income Tax	13.1	20.5	7.3
<b>Net income ex-4Bio</b>	<b>161.5</b>	<b>147.3</b>	<b>(14.2)</b>
as % of Gross Revenue	1.3%	1.2%	(0.1 pp)
<b>Net Income</b>	<b>173.2</b>	<b>159.0</b>	<b>(14.2)</b>
as % of Gross Revenue	1.4%	1.3%	(0.1 pp)

Balance Sheet (R\$ millions)	1Q26		Change
	Pre IFRS 16	IFRS 16	Δ 1Q26
<b>Assets</b>	<b>20,642.6</b>	<b>25,272.2</b>	<b>4,629.6</b>
<b>Current Assets</b>	<b>15,349.9</b>	<b>15,356.8</b>	<b>6.8</b>
Assets of Investment for Sale (4Bio)	1,512.8	1,519.3	6.5
Other Accounts Receivable	819.0	819.4	0.4
<b>Non-Current Assets</b>	<b>5,292.6</b>	<b>9,915.4</b>	<b>4,622.8</b>
Income Tax and Social Charges deferred	44.3	288.1	243.9
Other Credits	9.3	8.9	(0.4)
Investments	21.5	21.3	(0.2)
Right of use	0.0	4,379.5	4,379.5
<b>Liabilities and Shareholder's Equity</b>	<b>20,642.6</b>	<b>25,272.2</b>	<b>4,629.6</b>
<b>Current Liabilities</b>	<b>9,436.8</b>	<b>10,455.6</b>	<b>1,018.8</b>
Financial Leases	0.0	1,017.0	1,017.0
Liabilities of Investment for Sale (4Bio)	720.1	726.9	6.8
Other Accounts Payable	469.6	464.5	(5.1)
<b>Non-Current Liabilities</b>	<b>3,437.8</b>	<b>7,476.2</b>	<b>4,038.4</b>
Financial Leases	0.0	4,014.7	4,014.7
Income Tax and Social Charges Deferred	(23.7)	0.0	23.7
<b>Shareholder's Equity</b>	<b>7,768.0</b>	<b>7,340.4</b>	<b>(427.6)</b>
Income Reserves	2,489.1	2,075.7	(413.4)
Accrued Income	22.8	8.6	(14.2)

Cash Flow (R\$ millions)	1Q26		Change
	Pre IFRS 16	IFRS 16	Δ 1Q26
<b>Adjusted EBIT</b>	<b>548.3</b>	<b>649.1</b>	<b>100.8</b>
Non-Recurring Effects	(184.5)	(195.4)	(10.9)
Income Tax (34%)	(102.2)	(132.7)	(30.6)
Depreciation	274.1	524.8	250.6
Rental Expenses	0.0	(352.6)	(352.6)
Others	30.0	268.7	238.7
<b>Resources from Operations</b>	<b>698.6</b>	<b>894.7</b>	<b>196.1</b>
<b>Operating Cash Flow</b>	<b>536.3</b>	<b>536.3</b>	<b>0.0</b>
<b>Investments</b>	<b>(248.2)</b>	<b>(248.2)</b>	<b>0.0</b>
<b>Free Cash Flow</b>	<b>288.2</b>	<b>288.2</b>	<b>0.0</b>
<b>Total cash flow (ex-4Bio)</b>	<b>135.7</b>	<b>135.7</b>	<b>0.0</b>
<b>Total cash flow (with 4Bio)</b>	<b>112.0</b>	<b>112.0</b>	<b>0.0</b>

\*Includes adjustments to discounted receivables.

\*\*Includes NPV adjustments

\*\*\*Excludes NPV adjustments

## RESULTS CONFERENCE CALL

**May 06<sup>th</sup> 2026, 10:00 AM (BRT),  
With simultaneous translation to English.**

**Access Link**

<https://www.resultadosrdsaude.com.br/>

For more information, please contact our Investor Relations department: [ri@rdsaude.com.br](mailto:ri@rdsaude.com.br)

<b>Consolidated adjusted income statement</b>	<b>1Q25</b>	<b>1Q26</b>
(R\$ thousands)	Resubmitted	
<b>Gross revenue</b>	<b>9,947,886</b>	<b>11,979,521</b>
Taxes, deductions and returns	(674,904)	(1,410,932)
<b>Net revenue</b>	<b>9,272,982</b>	<b>10,568,589</b>
Cost of goods sold	(6,452,872)	(7,175,953)
<b>Gross profit</b>	<b>2,820,111</b>	<b>3,392,636</b>
Selling expenses	(1,902,460)	(2,275,228)
General and administrative expenses	(294,489)	(296,622)
<b>Operational expenses</b>	<b>(2,196,949)</b>	<b>(2,571,850)</b>
<b>Adjusted EBITDA</b>	<b>623,161</b>	<b>820,786</b>
Depreciation and amortization	(247,287)	(272,450)
<b>Operational earnings before financial results</b>	<b>375,874</b>	<b>548,335</b>
Financial expenses	(265,006)	(349,769)
Financial revenue	86,174	134,488
<b>Financial results</b>	<b>(178,831)</b>	<b>(215,281)</b>
Equity equivalence	(1,429)	(201)
<b>Earnings before income tax and social charges</b>	<b>195,614</b>	<b>332,853</b>
Income tax and social charges	(33,469)	(49,599)
<b>Adjusted net income ex-4Bio</b>	<b>162,145</b>	<b>283,254</b>
Results of discontinued operations	14,962	16,498
<b>Adjusted net income</b>	<b>177,107</b>	<b>299,752</b>

<b>Consolidated income statement</b>	<b>1Q25</b>	<b>1Q26</b>
(R\$ thousands)	Resubmitted	
<b>Gross revenue</b>	<b>9,947,886</b>	<b>11,979,521</b>
Taxes, deductions and returns	(674,904)	(1,410,932)
<b>Net revenue</b>	<b>9,272,982</b>	<b>10,568,589</b>
Cost of goods sold	(6,452,872)	(7,175,953)
<b>Gross profit</b>	<b>2,820,111</b>	<b>3,392,636</b>
Selling expenses	(1,902,460)	(2,275,228)
General and administrative expenses	(294,489)	(296,622)
Other operational expenses, net	(5,762)	(196,549)
<b>Operational expenses</b>	<b>(2,202,711)</b>	<b>(2,768,399)</b>
<b>EBITDA</b>	<b>617,399</b>	<b>624,237</b>
Depreciation and amortization	(247,287)	(272,450)
<b>Operational earnings before financial results</b>	<b>370,113</b>	<b>351,787</b>
Financial expenses	(265,006)	(349,769)
Financial revenue	86,174	146,525
<b>Financial results</b>	<b>(178,831)</b>	<b>(203,245)</b>
Equity equivalence	(1,429)	(201)
<b>Earnings before income tax and social charges</b>	<b>189,852</b>	<b>148,341</b>
Income tax and social charges	(31,510)	13,135
<b>Net income ex-4Bio</b>	<b>158,342</b>	<b>161,476</b>
Results of discontinued operations	22,783	11,720
<b>Net income</b>	<b>181,125</b>	<b>173,196</b>

<b>Assets</b> (R\$ thousands)	<b>1Q25</b>	<b>1Q26</b>
Cash and cash equivalents	352,269	441,802
Financial investments	65,795	95,934
Accounts receivable	2,090,777	2,835,139
Inventories	8,213,536	8,440,464
Taxes receivable	433,918	1,041,065
Anticipated expenses	145,122	158,787
Judicial deposits	3,017	4,886
Assets of investment for sale (4Bio)	1,641,850	1,512,830
Other accounts receivable	522,843	819,031
<b>Current assets</b>	<b>13,469,126</b>	<b>15,349,939</b>
Deposit in court	27,578	64,630
Taxes receivable	215,553	218,626
Income tax and social charges deferred	48,181	44,253
Other credits	19,864	9,293
Investments	13,663	21,488
Property, plant and equipment	2,693,141	2,929,600
Intangible	2,011,710	2,004,756
<b>Non-current assets</b>	<b>5,029,690</b>	<b>5,292,646</b>
<b>TOTAL ASSETS</b>	<b>18,498,816</b>	<b>20,642,585</b>
<b>Liabilities and shareholder equity</b> (R\$ thousands)	<b>1Q25</b>	<b>1Q26</b>
Suppliers	5,577,390	6,469,285
Loans and financing	672,158	425,458
Salaries and social charges payable	646,954	745,744
Taxes payable	377,395	423,363
Dividends and interest on equity	343,003	131,419
Provision for lawsuits	86,280	51,833
Liabilities of investment for sale (4Bio)	839,141	720,061
Other accounts payable	457,459	469,632
<b>Current liabilities</b>	<b>8,999,781</b>	<b>9,436,796</b>
Loans and financing	2,408,492	3,236,090
Provision for lawsuits	84,145	144,588
Income tax and social charges deferred	38,276	(23,735)
Other accounts payable	100,774	80,848
<b>Non-current liabilities</b>	<b>2,631,687</b>	<b>3,437,792</b>
Common stock	4,000,000	4,750,000
Capital reserves	117,894	149,004
Revaluation reserve	11,054	10,928
Income reserves	2,529,320	2,489,084
Accrued income	62,099	22,828
Equity adjustments	62,969	62,969
Non controller interest	14,117	-
Additional dividend proposed	69,895	283,184
<b>Shareholder equity</b>	<b>6,867,348</b>	<b>7,767,997</b>
<b>TOTAL LIABILITIES &amp; SHAREHOLDER EQUITY</b>	<b>18,498,816</b>	<b>20,642,585</b>

<b>Cash Flow (with 4Bio)</b>	<b>1Q25</b>	<b>1Q26</b>
<i>(R\$ thousands)</i>		
<b>Earnings before Income Tax and Social Charges</b>	<b>224,806</b>	<b>148,341</b>
<b>Adjustments</b>		
Depreciation and Amortization	247,811	274,127
Compensation plan with restricted shares, net	6,585	9,713
Interest over additional stock option	405	337
PP&E and Intangible Assets residual value	4,326	979
Provisioned Lawsuits	22,508	24,787
Provisioned Inventory Loss	12,435	(3,900)
Provision for Doubtful Accounts	(1,655)	814
Provisioned Store Closures	(2,608)	(147)
Interest Expenses	102,977	135,822
Debt Issuance Costs Amortization	2,384	2,216
Equity Equivalence Result	1,274	237
Provision for realization of recoverable investment	-	196,098
	<b>621,248</b>	<b>789,424</b>
<b>Assets and Liabilities variation</b>		
Clients and Other Accounts Receivable	(158,496)	(92,298)
Inventories	(205,748)	723,879
Other Short Term Assets	(142,954)	(513,710)
Suppliers	248,242	299,883
Salaries and Social Charges	(26,632)	(11,418)
Taxes Payable	101,935	(540,604)
Other Liabilities	(5,593)	8,735
Rents Payable	1,484	240
<b>Cash from Operations</b>	<b>433,486</b>	<b>664,131</b>
Interest Paid	(102,922)	(94,704)
Income Tax and Social Charges Paid	-	(30,354)
Paid lawsuits	(9,597)	(19,633)
<b>Net Cash from (invested) Operational Activities</b>	<b>320,967</b>	<b>519,440</b>
<b>Investment Activities Cash Flow</b>		
PP&E and Intangible Acquisitions	(270,528)	(259,952)
Restricted Investments	(50,089)	(76,814)
<b>Net Cash from Investment Activities</b>	<b>(320,617)</b>	<b>(336,766)</b>
<b>Financing Activities Cash Flow</b>		
Funding	90,000	(250,000)
Payments	(213,869)	-
Interest on Equity and Dividends Paid	(102)	(491)
<b>Net Cash from Funding Activities</b>	<b>(123,971)</b>	<b>(250,491)</b>
<b>Cash and equivalents in the beginning of the period (with 4Bio)</b>	<b>528,002</b>	<b>509,618</b>
Cash and equivalents net increase (with 4Bio)	(123,621)	(67,817)
<b>Cash and equivalents in the end of the period (with 4Bio)</b>	<b>404,381</b>	<b>441,801</b>